A Study to Find a Suitable Dose of Exl-111 for Further Research

NCT07356713 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Disease

Interventions

DRUG: Exl-111 (SAD)
DRUG: Exl-111 (MAD)
DRUG: Placebo
DRUG: Omalizumab

Sponsor

Excellergy Inc.